Anne M. Ercolini

Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.

Jean-Pascal Machiels, R. Todd Reilly, Leisha A. Emens et al. · PubMed · 2001 · 459 citations · Full text

Medicine, Immunology, Oncology +15

Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response

Anne M. Ercolini, Brian H. Ladle, Elizabeth A. Manning et al. · The Journal of Experimental Medicine · 2005 · 397 citations · Full text

Life Sciences, Immunology, Oncology +17

HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.

R. Todd Reilly, Morris B.C. Gottlieb, Anne M. Ercolini et al. · PubMed · 2000 · 216 citations · Full text

Medicine, Immunology, Oncology +16

The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.

R. Todd Reilly, Jean-Pascal Machiels, Leisha A. Emens et al. · PubMed · 2001 · 152 citations · Full text

Medicine, Immunology, Oncology +17

HER-2/neu-Specific Monoclonal Antibodies Collaborate with HER-2/neu-Targeted Granulocyte Macrophage Colony-Stimulating Factor Secreting Whole Cell Vaccination to Augment CD8+ T Cell Effector Function and Tumor-Free Survival in Her-2/ <i>neu</i> -Transgenic Mice

Matthew E. Wolpoe, Eric R. Lutz, Anne M. Ercolini et al. · The Journal of Immunology · 2003 · 105 citations · Full text

Medicine, Immunology, Oncology +17